Stereotaxis buys time and lowers cost GE allies with surgical company
The maker of the world's only magnetically controlled catheter navigation system now has more time to borrow less money. In negotiations with Silicon Valley Bank, Stereotaxis extended its credit line until March 31, 2010. But Stereotaxis voluntarily lowered its credit limit to $25 million from the previous $30 million. Stereotaxis president and CEO Mike Kaminski said the company did so because a recent influx of $20 million from investors reduced the potential need for borrowed cash. The lower credit limit also reduced the company's cost of borrowing, according to Kaminski.
Steris will combine its surgical technologies with x-ray and interventional systems from GE Healthcare under an agreement announced at last week's meeting in San Diego of the Society of Interventional Radiology. GE will provide the specialized x-ray equipment and interventional technologies. Steris will supply its HD 360° Suites featuring LED surgical lighting and visualization systems, integrated operating room technology, and equipment management systems. This is the second such deal between Steris and a major provider of imaging technology. Last October, the company cut a similar deal with Philips Healthcare for a combination of its suites and Philips' cardiovascular x-ray systems.
Multiple PACS, computed radiography systems, and dry imagers will be rolling into ENEL-MED in the wake of a contract struck by the Polish healthcare provider and Agfa. Six Agfa Impax systems will serve seven sites owned by the private facility. Eight CR systems and seven Drystar imagers will accompany the PACS. ENEL-MED cooperates with more than 360 medical institutions across Poland, providing services including teleradiology.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.